Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Short Interest Update

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) was the target of a significant decline in short interest in January. As of January 15th, there was short interest totaling 284,944 shares, a decline of 27.1% from the December 31st total of 391,100 shares. Based on an average daily trading volume, of 239,638 shares, the days-to-cover ratio is currently 1.2 days. Approximately 1.5% of the company’s stock are sold short. Approximately 1.5% of the company’s stock are sold short. Based on an average daily trading volume, of 239,638 shares, the days-to-cover ratio is currently 1.2 days.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its position in shares of Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after acquiring an additional 11,190 shares during the last quarter. Prelude Capital Management LLC purchased a new stake in shares of Artiva Biotherapeutics in the third quarter valued at about $41,000. Ground Swell Capital LLC purchased a new stake in shares of Artiva Biotherapeutics in the second quarter valued at about $38,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Artiva Biotherapeutics during the second quarter worth about $48,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics during the second quarter worth about $53,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Friday, October 17th. Wedbush raised their price objective on shares of Artiva Biotherapeutics from $18.00 to $23.00 and gave the company an “outperform” rating in a report on Friday, October 17th. HC Wainwright boosted their target price on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, January 27th. Finally, Jefferies Financial Group upgraded Artiva Biotherapeutics to a “strong-buy” rating in a research note on Tuesday, November 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

Artiva Biotherapeutics Price Performance

Shares of ARTV opened at $4.18 on Tuesday. Artiva Biotherapeutics has a 1-year low of $1.47 and a 1-year high of $7.36. The stock has a market cap of $102.62 million, a PE ratio of -1.62 and a beta of 2.92. The firm has a fifty day moving average price of $4.21 and a 200 day moving average price of $3.56.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.04. As a group, equities analysts expect that Artiva Biotherapeutics will post -4.95 EPS for the current fiscal year.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.